First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators-Reference-Cited by-同舟云学术

First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators

Published:2023 Issue:9 Volume:14 Page:1767-1777
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Abdel-Rahman Somaya A.¹²,Świderek Katarzyna³,Gabr Moustafa T.¹^ORCID

Affiliation:

1. Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA

2. Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

3. BioComp Group, Institute of Advanced Materials (INAM), Universitat Jaume I, 12071 Castellon, Spain

Abstract

The interaction of the inducible co-stimulator (ICOS) with its ligand (ICOSL) plays key roles in T-cell differentiation and activation of T-cell to B-cell functions.

Funder

Ministerio de Ciencia, Innovación y Universidades

Generalitat Valenciana

Ministerio de Ciencia e Innovación

European Social Fund

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MD/D3MD00150D

Reference87 articles.

1. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

2. Immune Checkpoint Inhibitors in Cancer Therapy

3. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

4. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

5. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of ICOS-targeted small molecules using affinity selection mass spectrometry screening;2024-08-07

2. Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors;ACS Medicinal Chemistry Letters;2024-05-28

3. Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction;Bioorganic & Medicinal Chemistry Letters;2024-02

4. Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma;Cancers;2024-01-19

5. Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches;Journal of Personalized Medicine;2024-01-04